Soon, India to get an app for drug recall notices, safety information

The DCGI believes the app will help improve patient safety by providing critical information online

cb
Aurobindo Pharma
BS Web Team New Delhi
Last Updated : Aug 31 2018 | 11:20 AM IST
Indians may soon be able to get all safety-related information about medicines on their mobiles as the country's drug regulator is about to launch a mobile app in this regard.

Citing sources, a report in Mint stated that the app will also facilitate users to send messages, report injuries and problems related to medical devices.

“The medical device reporting (MDR) will be one of the postmarket surveillance tools that will be used by the Central Drug Standards Controller Organization (CDSCO) to monitor device performance, detect potential device-related safety issues, and contribute to benefit-risk assessments of these products,” S Eswara Reddy, drug controller general of India (DCGI) told the business daily.

The app will help the regulator to fulfil one of the recommendations of an 11-member committee looking into the faulty hip implant case of Johnson and Johnson.


The committee had called for making drug-related information such as withdrawal by regulatory agency, voluntarily withdrawal by the company of drug or devices, safety and efficacy issues of drug or devices available online.

The panel had recommended the Ministry of Health should consider setting up an independent registry for tracking usage of high-risk medical devices in India. It also called for a detailed guidance document to be prepared by the CDSCO for effective recall of medical devices by the manufacturer or importer.

The DCGI believes the app will help improve patient safety by providing critical information online.

“We will encourage healthcare professionals, patient, and consumers to submit voluntary reports about serious adverse events that may be associated with a medical device, as well as use errors, product quality issues. These reports, along with data from other sources, can provide critical information that will help improve patient safety,” the business daily quoted Reddy.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story